📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. (2021)

First Author: Wall EC

Attributed to: G2P-UK; A National Virology Consortium to address phenotypic consequences of SARSCoV-2 genomic variation funded by COVID

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(21)01290-3

PubMed Identifier: 34090624

Publication URI: http://europepmc.org/abstract/MED/34090624

Type: Journal Article/Review

Volume: 397

Parent Publication: Lancet (London, England)

Issue: 10292

ISSN: 0140-6736